Evodiamine inhibits the proliferation of human osteosarcoma cells by blocking PI3K/Akt signaling

Oncology Reports

Volumn 34, Issue 3, 2015, Pages 1388-1396

  Meng, Zi Jun ^a   Wu, Nian ^a   Liu, Yang ^a   Shu, Ke Jie ^a   Zou, Xiang ^a   Zhang, Ran Xi ^a   Pi, Chang Jun ^a   He, Bai Cheng ^a   Ke, Zhen Yong ^a   Chen, Liang ^a   Deng, Zhong Liang ^a   Yin, Liang Jun ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Evodiamine; Osteosarcoma; Proliferation inhibition; PTEN PI3K Akt

Indexed keywords

AKT 1 PROTEIN; EVODIAMINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE B BETA; UNCLASSIFIED DRUG; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UPREGULATION; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; OSTEOSARCOMA; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; SIGNAL TRANSDUCTION;

EID: 84937231969     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4084     Document Type: Article

References (51)

1. Graudal N, Hubeck-Graudal T, Tarp S, Christensen R and Jurgens G: Effect of combination therapy on joint destruction in rheumatoid arthritis: A network meta-analysis of randomized controlled trials. PLoS One 9: e106408, 2014.
2. Tang N, Song WX, Luo J, Haydon RC and He TC: Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res 466: 2114-2130, 2008.
3. Mirabello L, Troisi RJ and Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the Surveillance, Epidemiology, and End Results Program. Cancer 115: 1531-1543, 2009.
4. Marina N, Gebhardt M, Teot L and Gorlick R: Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 9: 422-441, 2004.
5. Price CH: Osteogenic sarcoma; an analysis of the age and sex incidence. Br J Cancer 9: 558-574, 1955.
6. Weinfeld MS and Dudley HR Jr: Osteogenic sarcoma. A follow-up study of the ninety-four cases observed at the Massachusetts General Hospital from 1920 to 1960. J Bone Joint Surg Am 44-A: 269-276, 1962.
7. Dahlin DC and Coventry MB: Osteogenic sarcoma. A study of six hundred cases. J Bone Joint Surg Am 49: 101-110, 1967.
8. Ando K, Heymann MF, Stresing V, Mori K, Redini F and Heymann D: Current therapeutic strategies and novel approaches in osteosarcoma. Cancers (Basel) 5: 591-616, 2013.
9. Anderson PM and Pearson M: Novel therapeutic approaches in pediatric and young adult sarcomas. Curr Oncol Rep 8: 310-315, 2006.
10. Lin H, Tsai SC, Chen JJ, Chiao YC, Wang SW, Wang GJ, Chen CF and Wang PS: Effects of evodiamine on the secretion of testosterone in rat testicular interstitial cells. Metabolism 48: 1532-1535, 1999.
11. Chiou WF, Sung YJ, Liao JF, Shum AY and Chen CF: Inhibitory effect of dehydroevodiamine and evodiamine on nitric oxide production in cultured murine macrophages. J Nat Prod 60: 708-711, 1997.
12. Kobayashi Y: The nociceptive and anti-nociceptive effects of evodiamine from fruits of Evodia rutaecarpa in mice. Planta Med 69: 425-428, 2003.
13. King CL, Kong YC, Wong NS, Yeung HW, Fong HH and Sankawa U: Uterotonic effect of Evodia rutaecarpa alkaloids. J Nat Prod 43: 577-582, 1980.
14. Hong JY, Park SH, Min HY, Park HJ and Lee SK: Anti-proliferative effects of evodiamine in human lung cancer cells. J Cancer Prev 19: 7-13, 2014.
15. Zhang Y, Zhang QH, Wu LJ, Tashiro S, Onodera S and Ikejima T: Atypical apoptosis in L929 cells induced by evodiamine isolated from Evodia rutaecarpa. J Asian Nat Prod Res 6: 19-27, 2004.
16. Huang YC, Guh JH and Teng CM: Induction of mitotic arrest and apoptosis by evodiamine in human leukemic T-lymphocytes. Life Sci 75: 35-49, 2004.
17. Fei XF, Wang BX, Li TJ, Tashiro S, Minami M, Xing DJ and Ikejima T: Evodiamine, a constituent of Evodiae Fructus, induces anti-proliferating effects in tumor cells. Cancer Sci 94: 92-98, 2003.
18. Kan SF, Yu CH, Pu HF, Hsu JM, Chen MJ and Wang PS: Anti-proliferative effects of evodiamine on human prostate cancer cell lines DU145 and PC3. J Cell Biochem 101: 44-56, 2007.
19. Kan SF, Huang WJ, Lin LC and Wang PS: Inhibitory effects of evodiamine on the growth of human prostate cancer cell line LNCaP. Int J Cancer 110: 641-651, 2004.
20. Huang DM, Guh JH, Huang YT, Chueh SC, Chiang PC and Teng CM: Induction of mitotic arrest and apoptosis in human prostate cancer pc-3 cells by evodiamine. J Urol 173: 256-261, 2005.
21. Yang J, Cai X, Lu W, Hu C, Xu X, Yu Q and Cao P: Evodiamine inhibits STAT3 signaling by inducing phosphatase shatterproof 1 in hepatocellular carcinoma cells. Cancer Lett 328: 243-251, 2013.
22. Porta C, Paglino C and Mosca A: Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol 4: 64, 2014.
23. Zhang S and Yu D: PI(3)king apart PTEN's role in cancer. Clin Cancer Res 16: 4325-4330, 2010.
24. Mahimainathan L and Choudhury GG: Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase. J Biol Chem 279: 15258-15268, 2004.
25. Yoshimoto M, Cunha IW, Coudry RA, Fonseca FP, Torres CH, Soares FA and Squire JA: FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 97: 678-685, 2007.
26. Ishii N, Maier D, Merlo A, Tada M, Sawamura Y, Diserens AC and Van Meir EG: Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 9: 469-479, 1999.
27. Maehama T and Dixon JE: The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273: 13375-13378, 1998.
28. Franke TF, Kaplan DR, Cantley LC and Toker A: Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 275: 665-668, 1997.
29. He BC, Chen L, Zuo GW, Zhang W, Bi Y, Huang J, Wang Y, Jiang W, Luo Q, Shi Q, et al: Synergistic antitumor effect of the activated PPARgamma and retinoid receptors on human osteosarcoma. Clin Cancer Res 16: 2235-2245, 2010.
30. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW and Vogelstein B: A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95: 2509-2514, 1998.
31. He BC, Gao JL, Luo X, Luo J, Shen J, Wang L, Zhou Q, Wang YT, Luu HH, Haydon RC, et al: Ginsenoside Rg3 inhibits colorectal tumor growth through the downregulation of Wnt/ss-catenin signaling. Int J Oncol 38: 437-445, 2011.
32. Strzalka W and Ziemienowicz A: Proliferating cell nuclear antigen (PCNA): A key factor in DNA replication and cell cycle regulation. Ann Bot 107: 1127-1140, 2011.
33. Singha PK, Pandeswara S, Geng H, Lan R, Venkatachalam MA and Saikumar P: TGF-beta induced TMEPAI/PMEPA1 inhibits canonical Smad signaling through R-Smad sequestration and promotes non-canonical PI3K/Akt signaling by reducing PTEN in triple negative breast cancer. Genes Cancer 5: 320-336, 2014.
34. Marques RB, Aghai A, de Ridder CM, Stuurman D, Hoeben S, Boer A, Ellston RP, Barry ST, Davies BR, Trapman J, et al: High efficacy of combination therapy using PI3K/AKT inhibitors with androgen deprivation in prostate cancer preclinical models. Eur Urol: Sep 11, 2014 (Epub ahead of print) doi: 10.1016/j. eururo.2014.08.053.
35. Wang J, Chu ES, Chen HY, Man K, Go MY, Huang XR, Lan HY, Sung JJ and Yu J: microRNA-29b prevents liver fibrosis by attenuating hepatic stellate cell activation and inducing apoptosis through targeting PI3K/AKT pathway. Oncotarget 6: 7325-7338, 2014.
36. Yu P, Ye L, Wang H, Du G, Zhang J, Zhang J and Tian J: NSK-01105 inhibits proliferation and induces apoptosis of prostate cancer cells by blocking the Raf/MEK/ERK and PI3K/Akt/mTOR signal pathways. Tumour Biol 36: 2143-2153, 2015.
37. Cormier JN and Pollock RE: Soft tissue sarcomas. CA Cancer J Clin 54: 94-109, 2004.
38. Gorlick R, Anderson P, Andrulis I, Arndt C, Beardsley GP, Bernstein M, Bridge J, Cheung NK, Dome JS, Ebb D, et al: Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res 9: 5442-5453, 2003.
39. Wang L, Hu CP, Deng PY, Shen SS, Zhu HQ, Ding JS, Tan GS and Li YJ: The protective effects of rutaecarpine on gastric mucosa injury in rats. Planta Med 71: 416-419, 2005.
40. Yu X, Wu DZ, Yuan JY, Zhang RR and Hu ZB: Gastroprotective effect of fructus evodiae water extract on ethanol-induced gastric lesions in rats. Am J Chin Med 34: 1027-1035, 2006.
41. Liao CH, Pan SL, Guh JH, Chang YL, Pai HC, Lin CH and Teng CM: Antitumor mechanism of evodiamine, a constituent from Chinese herb Evodiae fructus, in human multiple-drug resistant breast cancer NCI/ADR-RES cells in vitro and in vivo. Carcinogenesis 26: 968-975, 2005.
42. Jiang J and Hu C: Evodiamine: a novel anti-cancer alkaloid from Evodia rutaecarpa. Molecules 14: 1852-1859, 2009.
43. Takada Y, Kobayashi Y and Aggarwal BB: Evodiamine abolishes constitutive and inducible NF-kappaB activation by inhibiting IkappaBalpha kinase activation, thereby suppressing NF-kappaB-regulated antiapoptotic and metastatic gene expression, upregulating apoptosis, and inhibiting invasion. J Biol Chem 280: 17203-17212, 2005.
44. Chien CC, Wu MS, Shen SC, Ko CH, Chen CH, Yang LL and Chen YC: Activation of JNK contributes to evodiamine-induced apoptosis and G2/M arrest in human colorectal carcinoma cells: a structure-activity study of evodiamine. PLoS One 9: e99729, 2014.
45. Chen MC, Yu CH, Wang SW, Pu HF, Kan SF, Lin LC, Chi CW, Ho LL, Lee CH and Wang PS: Anti-proliferative effects of evodiamine on human thyroid cancer cell line ARO. J Cell Biochem 110: 1495-1503, 2010.
46. Lee TJ, Kim EJ, Kim S, Jung EM, Park JW, Jeong SH, Park SE, Yoo YH and Kwon TK: Caspase-dependent and caspase-independent apoptosis induced by evodiamine in human leukemic U937 cells. Mol Cancer Ther 5: 2398-2407, 2006.
47. Yu H, Jin H, Gong W, Wang Z and Liang H: Pharmacological actions of multi-target-directed evodiamine. Molecules 18: 1826-1843, 2013.
48. Liu AJ, Wang SH, Chen KC, Kuei HP, Shih YL, Hou SY, Chiu WT, Hsiao SH and Shih CM: Evodiamine, a plant alkaloid, induces calcium/JNK-mediated autophagy and calcium/mitochondria-mediated apoptosis in human glioblastoma cells. Chem Biol Interact 205: 20-28, 2013.
49. Wang C, Li S and Wang MW: Evodiamine-induced human melanoma A375-S2 cell death was mediated by PI3K/Akt/caspase and Fas-L/NF-kappaB signaling pathways and augmented by ubiquitin-proteasome inhibition. Toxicol In Vitro 24: 898-904, 2010.
50. Ali IU, Schriml LM and Dean M: Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 91: 1922-1932, 1999.
51. Freeman SS, Allen SW, Ganti R, Wu J, Ma J, Su X, Neale G, Dome JS, Daw NC and Khoury JD: Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors. Cancer 113: 1453-1461, 2008.